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Abstract
Background: Serious inhaler technique errors can impair drug delivery to the lungs. This randomised, crossover,
open-label study evaluated the proportion of patients making predefined serious errors with Pulmojet compared
with Diskus and Turbohaler dry powder inhalers.
Methods: Patients ≥18 years old with asthma and/or COPD who were current users of an inhaler but naïve to the
study devices were assigned to inhaler technique assessment on Pulmojet and either Diskus or Turbohaler in a
randomised order. Patients inhaled through empty devices after reading the patient information leaflet. If serious
errors potentially affecting dose delivery were recorded, they repeated the inhalations after watching a training
video. Inhaler technique was assessed by a trained nurse observer and an electronic inhalation profile recorder.
Results: Baseline patient characteristics were similar between randomisation arms for the Pulmojet-Diskus (n = 277)
and Pulmojet-Turbohaler (n = 144) comparisons. Non-inferiority in the proportions of patients recording no
nurse-observed serious errors was demonstrated for both Pulmojet versus Diskus, and Pulmojet versus Turbohaler;
therefore, superiority was tested. Patients were significantly less likely to make ≥1 nurse-observed serious errors using
Pulmojet compared with Diskus (odds ratio, 0.31; 95 % CI, 0.19–0.51) or Pulmojet compared with Turbohaler
(0.23; 0.12–0.44) after reading the patient information leaflet with additional video instruction, if required.
Conclusions: These results suggest Pulmojet is easier to learn to use correctly than the Turbohaler or Diskus for
current inhaler users switching to a new dry powder inhaler.
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Background
Serious inhaler technique errors made by patients with
asthma and chronic obstructive pulmonary disease
(COPD) are common in real life with both pressurised
metered dose inhalers (pMDIs) and dry powder inhalers
(DPIs) despite advances in inhaler device technology [1, 2].
Although study results vary, estimates of those making
inhaler errors range up to 92 % of patients using pMDIs
[3] and up to 54 % of patients using DPIs [2].
There is increasing evidence to suggest that correct
inhaler technique (mastery) is fundamental for effective
therapy [1, 4, 5] and that inhaler device type and mastery
play important roles in improving adherence, clinical
outcomes, quality of life, and use of healthcare resources
[1, 6–10]. Poor inhaler technique can significantly reduce
effective delivery of the respirable fraction of the emitted
dose that reaches the lungs [5, 11–17]. Evidence suggests
that prescribers should consider inhaler technique and
ease of use before changing the dose of inhaled cortico-
steroids, switching to a different inhaler, or adding
other treatments to the regimen of patients with poorly
controlled asthma [11, 18]. Recent international asthma
guidelines highlight the importance of testing and en-
suring inhaler technique mastery, alongside checking
adherence, before increasing or changing therapy [19].
Correct inhaler technique involves some common steps
for all devices (dose preparation, device orientation, full
exhalation, deep inhalation, breath hold). However, dose
preparation and device orientation differ between devices,
highlighting the need for tailored patient training, testing,
and education [5, 6, 18, 20]. An important aspect of
inhaler mastery is the absence of serious inhaler technique
errors, defined as errors that could affect adequate dose
delivery to the lungs (also referred to as critical or major
errors [21, 22]). Innovative and reliable inhalers that are
associated with a reduced risk of serious errors, as com-
pared with current commonly used inhalers, are needed
to improve effective use, adherence, and disease control
[1, 5, 7, 14, 15, 23].
The Pulmojet®1 inhaler, shown in Fig. 1, is a new, pre-
filled DPI device that has been designed to minimise the
likelihood of serious errors by reducing the number of
steps required to prepare the dose. It has been designed
with a mechanism that releases the dose when a set inhal-
ation flow has been achieved. This ensures efficient de-
aggregation of the dose during each inhalation, and the
device can be held in any position (even downwards)
during dose preparation. This design may facilitate inhaler
device training, shortening its required duration and fre-
quency. The aim of this cross-sectional, randomised,
open-label study was to explore the proportion of patients
making serious errors during their first training session
with Pulmojet (not available for prescription during the
study) as compared with two other commonly used DPIs.
Methods
Study design and patients
The Handling Inhalers – Technique Error Comparison
(HI-TEC) Study was a single-visit, randomised, cross-
over, open-label study of patients with an established
diagnosis of asthma and/or COPD, designed to evaluate
serious errors in (a) the use of the patient’s own current
inhaler (Turbohaler®,2 Diskus®,3 or pMDI) and (b) the
first time use of a Pulmojet inhaler compared with a
Turbohaler or Diskus inhaler for patients naïve to test
devices (Fig. 2). The study was conducted between
September 2013 and March 2014 at general practices
in England and Scotland.
The study was performed in compliance with Good
Clinical Practice and in accordance with the principles
of the Declaration of Helsinki. It was approved by the
National Research Ethics Service Cambridge East Re-
search Ethics Committee (13/EE/0073) and by the NIHR
Coordinated System for Gaining NHS Permissions
(2013GP22 - 116238) (ClinicalTrials.gov Identifier:
NCT01794390). In addition, local National Health Service
(NHS) research governance approval was obtained from
all participating practices.
Fig. 1 The Pulmojet inhaler
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To be eligible for the study, patients were required to
meet the following inclusion criteria: age 18 years or
older, current asthma and/or COPD physician diagnosis,
current therapy including either inhaled corticosteroid
or fixed-dose combination inhaled corticosteroid/long-act-
ing beta-agonist administered through a pMDI, Turbohaler,
or Diskus device, and able and willing to read and compre-
hend written and verbal instructions and to provide written
informed consent. In addition, all patients using a Turboha-
ler or pMDI were required to have no use of the Diskus
device in the prior year (Diskus-naïve) and all patients using
a Diskus were required to have no use of the Turbohaler
device in the prior year (Turbohaler-naïve). No patients
had experience of Pulmojet, which remained unavailable
for prescription throughout the study.
Key exclusion criteria were receipt of oral corticoste-
roids and/or antibiotics for a lower respiratory condition
in the 4 weeks preceding the study and being considered
by the study nurse to be clinically unsuitable for study
inclusion for safety reasons (eg, unsafe for the patient to
perform multiple inhalations for error assessments and
flow measurements).
Eligible patients were identified from primary care
practices using routine electronic medical record data.
Patients who accepted the mailed invitation to participate
in the study were scheduled for a single study visit at
which their eligibility was confirmed, written informed
consent was recorded, and their inhaler technique was
assessed, as described below.
Phase 1
An electronic case report form was used to record pa-
tient demographic information and the routine clinical
assessment, including the number of exacerbations in
the previous 12 months, drawing on information in the
patient’s medical record as necessary.
Patients were told to withhold their morning medication
and to bring their current inhaler devices to the clinic.
They underwent assessment of their current inhaler tech-
nique, first using their active inhaler device and assessed
by trained nurse observers (using a predefined error
check-list). Second, patients were then asked to repeat
their inhalation manoeuvre using an empty version of
their current device (containing no drug or placebo for-
mulation), and their inhaler inhalation was assessed by an
electronic inhalation profile recorder (technology assess-
ment, described below).
Phase 2
Patients were allocated into the study comparison ac-
cording to their current device (see Fig. 2): current
pMDI and Turbohaler users were allocated to the
Pulmojet-Diskus comparison and current Diskus users
were allocated to the Pulmojet-Turbohaler comparison.
The pMDI users were included in the Pulmojet-Diskus
comparison to attain the greater numbers required ac-
cording to the power calculations (see below).
The study was conducted by primary care respiratory
research nurses who had prior experience and received
instruction in inhaler device assessment for the study.
To ensure that patient training on the different devices
(Pulmojet, the investigative device, and Turbohaler or
Diskus, the control devices) was consistent and represen-
tative of best standard care, two forms of patient training
were utilised: provision of the device’s patient information
leaflet and, for those making one or more errors post-
leaflet, an instructional video. The training video was
designed to be representative of a standardised form of
Fig. 2 Study design showing phases 1 and 2
Chrystyn et al. BMC Pulmonary Medicine  (2016) 16:12 Page 3 of 14
optimal training by a qualified nurse. It was reviewed and
approved by the full study steering committee.
After randomisation to device order, the first allocated
device and accompanying patient information leaflet
were provided to patients; they were given up to 5 min
to read the leaflet after which they were evaluated for
device handling technique, first by the research nurse, as
evaluated against a predefined list of errors, and then via
pneumotrac spirometer (details are below). If the research
nurse observed no serious errors, testing on the first
device was considered to have been completed and the
patient was given the second allocated device. If one or
more serious errors were observed in the patient’s hand-
ling of the first allocated device, the patient continued to
video training and their technique was re-evaluated using
both nurse-observed and technology assessments. They
then repeated the same process for the second device.
Inhaler technique assessment
Inhaler technique was evaluated by both (a) a nurse
observer qualified to identify serious errors in device
handling technique (see Additional file 1 for the list of
predefined errors) and (b) the measurement of an inhal-
ation profile (technology assessment of the inhalation
manoeuvre). Inhalation flow against time measurements
were downloaded using the inhaler attached to the inlet
of a pneumotrac spirometer (Vitalograph Ltd, Maids
Moreton, Buckingham, UK) so that patients were
instructed to inhale through the spirometer as though
through the inhaler device, as previously described [24].
At the end of the study visit, which lasted 1 h, and
only after the study device training was completed,
patients who demonstrated errors in current device hand-
ling were retrained by the study nurse to use their current
device correctly.
All devices were empty and since no active medication
was administered, efficacious and safe use were not
assessed.
Statistical analysis
Determination of sample size
The objective of the analyses was to demonstrate non-
inferiority, and, if met, to evaluate for superiority of the
Pulmojet device compared with Diskus and Turbohaler
in terms of ability to achieve inhaler mastery after stan-
dardised training.
The sample sizes were calculated using nQuery Advisor
7.0 (Statistical Solutions, Ltd., Cork, Ireland) and were
optimised to maximise power for the primary compari-
sons (see Additional file 2 for details). Based on primary
care audit data from 336 patients, we estimated a success
rate of 78.2 % for the Diskus inhaler and a success rate of
38.8 % for Turbohaler. We further estimated the propor-
tion of discordant pairs in the Diskus-naïve vs. Pulmojet
comparison to be 0.282 and the proportion of discordant
pairs in the Turbohaler-naïve vs. Pulmojet comparison to
be 0.563. To test for non-inferiority, the sample size
required for the Diskus-naïve vs. Pulmojet comparison to
achieve 90 % power (5 % level of significance, one-sided
test) was 226, assuming an expected difference in pro-
portions of 0.00 and allowing a difference in propor-
tions (Pulmojet-Diskus) no lower than −0.10. Thus, it
was determined that 113 patients would be randomised
to Pulmojet first and a further 113 to Diskus first. For
the Turbohaler-naïve vs. Pulmojet comparison, the
sample size required to achieve 90 % power (5 % level
of significance, one-sided test) was 122, assuming an
expected difference in proportions of 0.10 and allowing
a difference in proportions (Pulmojet-Turbohaler) no
lower than −0.10. Sixty-one patients would, therefore,
be randomised to Pulmojet and then Turbohaler and
61 to Turbohaler and then Pulmojet assessments.
The total number of patients required to achieve 90 %
power was therefore 348. We anticipated an 8 % dropout
rate based on a review of anonymous medical records
(data not shown); thus, it was determined that 376
patients would be recruited into the study.
Subsequent to the completion of the study it was deter-
mined that the per-protocol power calculation underesti-
mated the number of patients required. This is because
the 95 % CIs (two-sided) for the non-inferiority calcula-
tion are actually equivalent to a one-sided test with 2.5 %
significance. A post-hoc revised power calculation, using
the assumptions noted above, and 2.5 % significance level,
would have required 276 patients for the Pulmojet-Diskus
comparison and 148 patients for the Pulmojet-Turbohaler
comparison. As noted below, in fact the numbers of eli-
gible patients included in the analyses were 277 and 144,
respectively (421 total), which essentially also met the
95 % CIs (two-sided) for the non-inferiority calculation
and one-sided test with 2.5 % significance needs of the
post-hoc power calculation.
Baseline data
Baseline data were analysed for all enrolled patients and
for the full analysis set, which included all patients who
completed an assessment of nurse-observed errors on
both study devices. Descriptive statistics were used to
summarise patient demographic and baseline clinical
characteristics. Current device arms were compared
using parametric or non-parametric tests, as appropriate:
for variables measured on the interval or ratio scale, an
F-test or Kruskal-Wallis test (depending on the distribu-
tion of the variable) was used; for categorical variables, a
Pearson’s χ2 (or Fisher’s exact test if cell sizes were suffi-
cient) was used. Randomisation orders were compared
for patient baseline characteristics using the Mann–
Whitney and χ2 test.
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Outcome measures
All analyses were carried out using the full analysis set,
thus permitting a paired analysis of results.
Primary endpoint
To determine non-inferiority in device handling of the
Pulmojet compared with the comparator device (Diskus
or Turbohaler), the proportions of patients achieving an
absence of serious errors on each device, and the differ-
ence in proportions, were analysed using a conditional
binary logistic regression model. Non-inferiority in de-
vice handling was considered to have been achieved if
the proportion of patients recording an absence of
nurse-observed serious errors on the Pulmojet was no
more than 10 % lower than the proportion of patients
recording an absence of nurse-observed serious errors
on the comparator device, namely, if the lower bound of
the 95 % CI of the difference in proportions of patients
recording an absence of serious errors was > −0.10.
Where non-inferiority was demonstrated, superiority
was evaluated and claimed if the proportion of patients
recording no nurse-observed serious errors on the Pul-
mojet was significantly greater than the proportion of
patients recording no nurse-observed serious errors on
the comparator device, namely, if the lower bound of
the 95 % CI of the difference in proportions of patients
recording no serious errors was >0.00. To provide an
additional measure of effect size, a conditional logistic
regression was used to compare the odds of recording a
serious error. Superiority was also shown if the 95 % CI
for the odds ratio of recording an error using Pulmojet
compared with the comparator device fell entirely to the left
of 1.00. The number of nurse-observed inhaler technique
errors was summarised and compared between inhaler
types using the Wilcoxon matched pair signed-rank test.
Post-hoc sensitivity analysis
A post-hoc sensitivity analysis restricted to errors that
were definitely serious (ie, those that would definitely
preclude adequate dose delivery to the lungs) was also
conducted.
Secondary endpoint
Technology-assessed inhalation errors (defined as errors
recorded by the pneumotrac spirometer) were combined
Fig. 3 Disposition of study patients
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with nurse-observed serious errors (excluding inhalation
errors).
Statistically significant results were defined as p < 0.05.
All analyses were carried out using SPSS version 22, SAS
version 9.3, and Microsoft Office EXCEL 2007.
Results
Patients
Figure 3 shows the disposition of patients recruited into the
study. Although the planned recruitment was 376 patients,
430 patients were actually recruited because of simultan-
eous recruitment across multiple sites. Of 430 recruited
patients, 421 (98 %) completed the study and were included
in the full analysis set (all patients who completed an
assessment of nurse-observed errors on both study
devices).
Table 1 presents baseline patient characteristics for the
Diskus-naïve vs. Pulmojet-naïve and Turbohaler-naïve
vs. Pulmojet-naïve comparisons. Patients first rando-
mised to Turbohaler in the Pulmojet vs. Turbohaler
comparison had received significantly more courses of
oral corticosteroids in the 12 months before entry into
the study than did those first randomised to Pulmojet.
There were no other statistically significant differences
between treatment cohorts (Table 1).
Phase 1
Patients were first assessed for inhaler technique using
their current device: 92 % of patients using a pMDI,
39 % of those using Diskus, and 76 % of those using the
Turbohaler made one or more serious errors (nurse ob-
served and technology assessed, detailed data not shown).
Primary endpoint: nurse-observed serious errors
Pulmojet vs. Diskus
Table 2 shows that more patients made errors with Diskus
compared with Pulmojet and non-inferiority was found.
Further analysis revealed superiority in that patients naïve
to both devices had significantly lower odds of making a
nurse-observed serious error (p < 0.001), and overall they
Table 1 Baseline patient characteristics
Characteristic Pulmojet vs. Diskus Pulmojet vs. Turbohaler
First randomised device First randomised device
Pulmojet Diskus Pulmojet Turbohaler
(n = 136) (n = 141) (n = 74) (n = 70)
Female sex, n (%) 89 (65.4) 91 (64.5) 32 (43.2) 35 (50.0)
Age, mean (SD) 52.5 (10.9) 51.4 (10.5) 60.7 (10.1) 59.5 (11.7)
BMI (kg/m2), mean (SD) 29.5 (6.9) 30.4 (6.6) 29.4 (7.3) 28.1 (7.1)
Smoking status, n (%)
Current smoker 21 (15.4) 25 (17.7) 14 (18.9) 23 (32.9)
Ex-smoker 50 (36.8) 47 (33.3) 43 (58.1) 34 (48.6)
Non-smoker 65 (47.8) 69 (48.9) 17 (23.0) 13 (18.6)
Diagnosis, n (%)
Asthma 118 (86.8) 114 (80.9) 23 (31.1) 29 (41.4)
COPD 17 (12.5) 23 (16.3) 51 (68.9) 41 (58.6)
Asthma & COPD 1 (0.7) 4 (2.8) 0 (0) 0 (0)
FEV1 %predicted, mean (SD)
b 84 (21) 84 (22) 69 (23) 70 (25)
FEV1/FVC, mean (SD)
b 0.78 (0.15) 0.75 (0.15) 0.63 (0.16) 0.66 (0.17)
Oral corticosteroid courses, n (%)a
1 course 21 (15.6) 17 (12.1) 11 (15.1) 22 (31.9)*
≥2 courses 21 (15.6) 14 (9.9) 15 (20.5) 17 (24.6)
Inpatient admission, n (%)a
≥1 admissions 10 (7.4) 6 (4.3) 5 (6.8) 3 (4.3)
Emergency department attendance, n (%)a
≥1 visits 11 (8.1) 8 (5.7) 3 (4.1) 2 (2.9)
COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
*χ2 test p < 0.05 for the two-way comparison; all other comparisons were non-significant
aPatient-reported with regard to prior year
bFEV1 and FEV1/FVC data were available for 128 (94 %) and 128 (91 %) of patients first randomised to Pulmojet and Diskus, respectively, and for 71 (96 %) and 68
(97 %) patients first randomised to Pulmojet and Turbohaler, respectively
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made significantly fewer nurse-observed serious errors,
when using the Pulmojet device compared with Diskus,
having read the leaflet and, if required, watched an in-
structional video (Fig. 4; Tables 2 and 3).
The post-leaflet nurse-observed serious errors cate-
gorised into preparation, positioning, inhalation, and gen-
eral knowledge errors are presented in Fig. 5a (see
Additional file 1 for further details). More patients made
more general knowledge and inhalation errors with Diskus
than with Pulmojet, whereas more patients made prepar-
ation errors with Pulmojet than with Diskus. In addition,
26 % of patients made a positioning error with the Diskus.
Figure 5b shows that post-leaflet and post-leaflet + video,
more patients made inhalation and preparation errors
with Diskus compared with Pulmojet; in addition, there
were positioning errors with the Diskus. As the Pulmojet
device is not subject to positioning error, no positioning
errors were identified with Pulmojet. On the other hand,
more patients did not know how to determine when the
device was empty, which was considered a general know-
ledge error, with Pulmojet than with Diskus (details in
Additional file 1: Tables S1 and S2).
The numbers of patients making 0, 1, and ≥2 serious
errors are summarised in Table 3.
Pulmojet vs. Turbohaler
Table 2 and Fig. 4 show non-inferiority and also super-
iority in that fewer patients made nurse-observed serious
Table 2 Nurse-observed serious errors for Diskus vs. Pulmojet and Turbohaler vs. Pulmojet comparisons: post-patient information
leaflet alone and post-leaflet and instructional video
First randomised device Non-inferiority
Pulmojet vs. Diskus Pulmojet Diskus Proportions of patients with no errors:
(n = 277) (n = 277) Difference (95 % CI)
Post-patient information leaflet alone
No serious error, n (%) 110 (39.7) 74 (26.7) 0.13 (0.05–0.21)
≥1 errors, n (%) 167 (60.3) 203 (73.3) –
Post-patient information leaflet and instructional video (primary endpoint)
No serious error, n (%) 215 (77.6) 170 (61.4) 0.16 (0.09–0.24)
≥1 errors, n (%) 62 (22.4) 107 (38.6) –
Pulmojet vs. Turbohaler Pulmojet (n = 144) Turbohaler (n = 144)
Post-patient information leaflet alone
No serious error, n (%) 59 (41.0) 25 (17.4) 0.24 (0.13–0.34)
≥1 errors, n (%) 85 (59.0) 119 (82.6) –
Post-patient information leaflet and instructional video (primary endpoint)
No serious error, n (%) 106 (73.6) 69 (47.9) 0.26 (0.15–0.37)
≥1 errors, n (%) 38 (26.4) 75 (52.1) –
Fig. 4 Odds ratio for ≥1 nurse-observed serious errors with Pulmojet relative to Diskus or Turbohaler DPI. (Post-leaflet + video was the primary
endpoint.) *Conditional logistic regression (p < 0.001 for all comparisons)
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errors with Pulmojet compared with Turbohaler after
the leaflet and video instruction, as well as the leaflet
alone. Many patients made more than one error, particu-
larly post-leaflet alone (Table 3).
Serious errors by type are shown in Fig. 6a and b. In
addition to making positioning errors with Turbohaler,
more patients made general knowledge, inhalation, and
preparation errors with Turbohaler than with Pulmojet
(Additional file 1: Tables S3 and S4).
Post hoc sensitivity analysis
The sensitivity analysis examining errors that were defin-
itely serious (those that would definitely preclude
adequate dose delivery to the lungs; see Additional file 1:
Tables S1–S4) found that non-inferiority remained for
both comparisons (Pulmojet vs. Diskus and Pulmojet vs.
Turbohaler), post-leaflet alone and post-leaflet and in-
structional video (Table 4).
Post-leaflet alone, for the Pulmojet vs. Diskus compari-
son, superiority was no longer shown (Table 4). Overall,
both preparation and inhalation errors were lower with
Pulmojet than Diskus (Additional file 1: Tables S1 and S2).
Post-leaflet and instructional video, superiority was shown.
Preparation errors with Pulmojet were very low, while
inhalation errors with Diskus remained high.
For the Pulmojet vs. Turbohaler comparison, superior-
ity was shown both post-leaflet alone and post-leaflet
and instructional video, with high preparation errors for
Turbohaler in both cases (Table 4; Additional file 1:
Tables S3 and S4).
Secondary endpoint: combined serious errors (nurse-
observed and technology-assessed)
Table 5 shows superiority of Pulmojet use when
technology-assessed errors were combined with nurse-
observed errors.
Discussion
Results of the current study suggest that Pulmojet may be
easier to learn to use correctly than either the Diskus or
Turbohaler for current inhaler users who are switched to
a new device. Patients with asthma and/or COPD were
significantly less likely to make a nurse-observed serious
error with Pulmojet than with Diskus or Turbohaler after
receiving training by either the patient information leaflet
alone or the leaflet and as-needed additional video instruc-
tion. Mastery of the inhalation technique is, therefore,
more likely to be readily achieved with Pulmojet than
either Diskus or Turbohaler. Designing inhaler devices to
make them easier to use and teach is essential for improv-
ing long-term outcomes in asthma and COPD, so an
important factor to consider when choosing a specific
device is whether or not the patient is capable of using it
correctly to achieve adequate drug delivery [25]. Further-
more, the ease of correct use of inhalers and patient pref-
erence for device can affect adherence with treatment and
clinical outcomes [1, 5, 7, 14–16, 23–26].
Patients were not given verbal instructions alongside
the patient information leaflet, so the use of the leaflet
on its own mimicked common clinical practice (al-
though sometimes patients may be verbally trained as
well when prescribed a new device). We found that, for
all inhalers tested, fewer serious errors were observed
after patients read the patient information leaflet and
watched an instructional video than after reading the
leaflet alone. Our findings are in line with other reports
that written or passive instructions alone, such as the
patient information leaflets, are not sufficient to teach
correct inhalation technique; and other tools, such as
verbal instructions, multimedia educational materials,
demonstrations, and practice sessions are needed to im-
prove inhaler device technique [25–35]. Crompton et al.
[26] have also recommended that the teaching of correct
inhalation techniques should be tailored to each patient’s
needs and preferences; for example, multimedia methods
may be more beneficial for younger patients, while one-
to-one tuition is more suitable for elderly patients. The
fact that errors in device technique remained after the
instructional video suggests that instructional videos are
useful but may not be adequate to ensure optimal device
technique for all patients.
The comparator devices chosen for this study, the Diskus
and the Turbohaler, are two of the most frequently pre-
scribed multidose DPI devices worldwide. Previously
reported incidence of serious errors ranges from 21–35 %
with Diskus and 37–44 % with Turbohaler [1, 10]. The
current device error data (study phase 1) showed a similar
incidence for Diskus use (39 %) but greater error rates
amongst the Turbohaler users (76 %). The high inhaler
technique error rate amongst current pMDI users (92 %)
was consistent with previous data [3].
Table 3 Number of patients making 0, 1, and ≥2 nurse-observed
serious errors (post-patient information leaflet alone and post-leaflet
and instructional video)
First randomised device
Pulmojet vs. Diskus Pulmojet vs. Turbohaler
Pulmojet Diskus Pulmojet Turbohaler
(n = 277) (n = 277) (n = 144) (n = 144)
Post-patient information leaflet alone
0 errors, n (%) 110 (39.7) 74 (26.7) 59 (41.0) 25 (17.4)
1 error, n (%) 82 (29.6) 76 (27.4) 40 (27.8) 24 (16.7)
≥2 errors, n (%) 85 (30.7) 127 (45.8) 45 (31.3) 95 (66.0)
Post-patient information leaflet and instructional video
0 errors, n (%) 215 (77.6) 170 (61.4) 106 (73.6) 69 (47.9)
1 error, n (%) 43 (15.5) 64 (23.1) 26 (18.1) 36 (25.0)
≥2 errors, n (%) 19 (6.9) 43 (15.5) 12 (8.3) 39 (27.1)
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The Pulmojet device has been designed to release its
dose at a low minimum inspiratory flow. In-house mea-
surements have identified that the dose is released from
a Pulmojet at ≥25 L/min (unpublished data), which is
below the recognised minimum inspiratory flow of the
Turbohaler [36–38] and the Diskus [39]. This ensures
efficient de-aggregation of the dose during each inhal-
ation so that drug particles most likely to be deposited
into the airways are entrained in the inhaled airstream
leaving the device. The Pulmojet inhaler has been
designed with audio, visual, and sensory feedback mech-
anisms to indicate that an adequate inhalation has been
performed, a feature appreciated by patients [40],
whereas neither the Turbohaler nor Diskus provides any
feedback to the patient that an adequate inspiratory flow
has been achieved. Furthermore, because the dose is not
released until a set inhalation flow is achieved, the Pul-
mojet can be held in any orientation during dose
preparation.
Patients attending UK primary care practices were
recruited for this study, and minimal exclusion criteria
other than evidence of recent exacerbation or lower
respiratory tract infection were applied to enable the
study results to be generalisable to most patients with
asthma and/or COPD receiving ICS or fixed-dose com-
bination therapy in routine practice. Asthma, COPD and
asthma-COPD were diagnoses made by the patients’
physicians according to their standard clinical practices,
a
b
Fig. 5 a. Percentage of patients recording Pulmojet and Diskus errors post-leaflet alone. b. Percentage of patients recording Pulmojet and Diskus
errors post-leaflet and instructional video
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and we included both ICS and fixed-dose combinations
as both are commonly prescribed for asthma and
COPD in clinical practice [41]. Other strengths of this
investigation include the randomised assignment to
device training order, assessments made by trained
independent nurses, and blinding of data analysts and
statisticians. The practical importance of identifying
superiority (rather than just non-inferiority) should also
be recognised, as despite the ease of use of any one
device compared with another, the overall management
of chronic respiratory conditions is associated with a
complex array of management issues, and hence it
would be practically acceptable for a switch in device
only if superiority were shown.
We acknowledge several limitations of the current
research. Firstly, this was an open-label study that
involved subjective assessment, and hence potential
nurse bias, although efforts were made to standardise
demonstration of devices and training in assessment of
serious errors. Secondly, this study focused on self-
training techniques (both the patient information leaflet
and video are tools that the patient can employ at
home); whereas, in practice, healthcare providers might
incorporate their own educational style when training
device-naïve patients for the first time (ie, the education
may not be standardised in real life). Furthermore,
although errors were defined by independent expert
consensus, they were not validated as being serious.
a
b
Fig. 6 a. Percentage of patients recording Pulmojet and Turbohaler errors post-leaflet alone. b. Percentage of patients recording Pulmojet and
Turbohaler errors post-leaflet and instructional video
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However, in the post-hoc sensitivity analysis restricted to
errors that were definitely serious (ie, those that would
definitely preclude adequate dose delivery to the lungs),
the results remained largely the same. We included “in-
halation is not forceful from the start” as a serious error
based on the recommendations for DPI use of a recent
European Respiratory Society/International Society for
Aerosols in Medicine task force [42].
Another limitation is the fact that this study does not
provide insight into maintenance of inhaler mastery or its
impact on disease control. Learning to correctly handle a
device is a continuous process and inhaler technique can
decline over time [34], so it would be interesting to deter-
mine whether the superior results in inhaler technique
observed with Pulmojet vs. Diskus and Turbohaler are
maintained after a period of use and whether this is
Table 5 Combined serious errors (nurse-observed and technology-assessed) for Diskus vs. Pulmojet and Turbohaler vs. Pulmojet
comparisons: post-patient information leaflet alone and post-leaflet and instructional video
First randomised device Superiority
Pulmojet vs. Diskus Pulmojet
(n = 272)
Diskus
(n = 272)
Odds ratio (95 % CI) for Pulmojeta
relative to comparator (1.00)
p-valuea
Post-patient information leaflet alone
≥1 errors, n (%) 148 (54.4) 175 (64.3) 0.61 (0.42–0.90) 0.012
Post-patient information leaflet and instructional video
≥1 errors, n (%) 56 (20.6) 87 (32.2)b 0.48 (0.31–0.75) 0.001
Pulmojet vs. Turbohaler Pulmojet (n = 144) Turbohaler (n = 142)
Post-patient information leaflet alone
≥1 errors, n (%) 79 (54.9) 121 (85.2) 0.16 (0.08–0.34) <0.001
Post-patient information leaflet and instructional video
≥1 errors, n (%) 38 (26.4) 93 (65.5) 0.10 (0.04–0.23) <0.001
aConditional logistic regression
bn = 270
Table 4 Nurse-observed, definitely serious errors for Diskus vs. Pulmojet and Turbohaler vs. Pulmojet comparisons: post-patient infor-
mation leaflet alone and post-leaflet and instructional video (post-hoc sensitivity analysis)
First randomised device Non-inferiority Superiority
Pulmojet vs. Diskus Pulmojet Diskus Proportions of patients with no
errors: Difference (95 % CI)
Serious error with Pulmojeta relative to
comparator (1.00): Odds ratio (95 % CI) p-valuea
(n = 277) (n = 277)
Post-patient information leaflet alone
No definitely serious
error, n (%)
147 (53.1) 129 (46.6) 0.06 (−0.02 to 0.15) – –
≥1 errors, n (%) 130 (46.9) 148 (53.4) – 0.74 (0.51–1.06) 0.099
Post-patient information leaflet and instructional video
No definitely serious
error, n (%)
229 (82.7) 206 (74.4) 0.08 (0.01–0.15) – –
≥1 errors, n (%) 48 (17.3) 71 (25.6) – 0.45 (0.26–0.78) 0.004
Pulmojet vs.
Turbohaler
Pulmojet
(n = 144)
Turbohaler
(n = 144)
Post-patient information leaflet alone
No definitely serious
error, n (%)
78 (54.2) 44 (30.6) 0.24 (0.13–0.35) – –
≥1 errors, n (%) 66 (45.8) 100 (69.4) – 0.26 (0.14–0.49) <0.001
Post-patient information leaflet and instructional video
No definitely serious
error, n (%)
115 (79.9) 85 (59.0) 0.21 (0.10–0.31) – –
≥1 errors, n (%) 29 (20.1) 59 (41.0) – 0.32 (0.17–0.58) <0.001
aConditional logistic regression
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associated with better disease control. Moreover, patients
considered as first-time users with regard to the Diskus or
Turbohaler devices could potentially have used them in the
past, more than 1 year before their inclusion in the study.
In such cases, it is possible that any differences with the
Pulmojet device would have been minimised or, conversely,
that for patients switched at some time preceding the prior
year from Diskus or Turbohaler because they could not
handle it well, a comparison with Pulmojet would lead to a
relatively favourable outcome for Pulmojet. However, we
believe that patients using these devices previous to the
1 year were few if any. Finally, all enrolled patients were
current inhaler users and hence our findings may not apply
to patients prescribed an inhaler for the first time.
Conclusions
In patients with asthma and/or COPD who were given in-
haler devices without proper training, fewer errors were
made when using the Pulmojet for the first time when
compared with Diskus and Turbohaler devices. These
findings suggest that Pulmojet is a device that is easier to
teach, easier to learn to use correctly, and easier to use.
Thus, device mastery is more likely when using Pulmojet
compared with Diskus or Turbohaler. The improvements
after patients watched an instructional video suggest that
videos could be useful for some individuals to comple-
ment inhaler technique training. In addition, the study
design used here provides an adequate framework for
future studies aimed at comparing the ease of effective
training and use of other inhaler devices.
Endnotes
1Pulmojet® is a registered trademark in the property of
Zentiva (Zentiva Group, a.s., Prague, Czech Republic)
2Turbohaler® is a registered trademark of the AstraZe-
neca group of companies
3Diskus® is a registered trademark of the GSK group of
companies
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